Pancreatic Cancer Therapy Trial Starts
Posted on: Thursday, 15 March 2007, 12:00 CDT
British researchers are to begin a pancreatic cancer therapy trial, testing a new vaccine against two chemotherapy drugs.
The University of Liverpool study will involve patients with advanced and metastatic pancreatic cancer. The vaccine, GV1001, is a new immunotherapeutic drug for pancreatic cancer developed by Pharmexa, a Danish biotech company.
One of the 10 most common cancers in the United Kingdom and one of the most difficult to diagnose, pancreatic cancer victims usually die within a year of diagnosis.
The Phase III trial designed by Britain's National Cancer Research Institute will test GV1001 alongside two chemotherapy drugs -- gemcitabine and capecitabine.
GV1001 is a particularly attractive vaccine; the antigen that it targets is expressed on virtually all pancreatic cancer cells and the vaccine stimulates the production of all of the cells that are required for an effective immune attack upon these cancers, said the trial's chief investigator, Dr Gary Middleton of the Royal Surrey County Hospital. Adding it to the platform of chemotherapy is an exciting strategy which, if successful, would create a new standard of care in this disease.
Source: United Press International
Related Articles
- New Test to Predict How Breast Cancer Patients Respond to Chemotherapy
- Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer After First-Line Chemotherapy
- Data From Satraplatin SPARC Phase 3 Trial in Patients With Hormone-Refractory Prostate Cancer Progressing After Initial Chemotherapy Presented at 44th ASCO Annual Meeting
- GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
- Antigenics Cancer Vaccine Successful in Trial
- Sinovac Attended 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials
- Community Oncology Alliance Refutes NBC Nightly News Story 'Cancer Docs Profit From Chemotherapy Drugs'
- Chemokine Cancer Drug in Phase 1b/2 Trial
- CANCER Experts to Launch UK Trials
- Phase III Study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19
 |
 |
User Comments (0)
RSS Feeds